[Skip to content]

Print this page

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260 261-280; 281-300; 301-320; 321-340

NICE TAs 281-300






DHFT Formulary link

East Midlands Cancer Network link (cancer drugs only)



Gout - canakinumab (terminated appraisal) (TA281)

Not recommended by NICE



Idiopathic pulmonary fibrosis - pirfenidone (TA282)

To be initiated only by tertiary specialist centre



Macular oedema (retinal vein occlusion) - ranibizumab (TA283)

11.8 Miscellaneous ophthalmic preparations




Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)

Not recommended by NICE




Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab (TA285)

Not recommended by NICE




Schizophrenia or bipolar disorder - loxapine inhalation (terminated appraisal) (TA286)

NICE Appraisal terminated



Pulmonary embolism and preventing recurrent venous thromboembolism - rivaroxaban (TA287)

 2.8.2 Oral anticoagulants



Type 2 diabetes - Dapagliflozin combination therapy (TA288)

 6.1.1 - Insulin, oral antidiabetic drugs, biguanides



Myelofibrosis (splenomegaly, symptoms) - ruxolitinib (TA289)

Not recommended by NICE



Overactive bladder - mirabegron (TA290)

7.4.2 Drugs for Urinary Frequency, Enuresis and Incontinence



Gout (tophaceous, severe debilitating, chronic) - pegloticase (TA291)

Not recommended by NICE



Bipolar disorder (adolescents) - aripiprazole (TA292)

4.2.1  Antipsychotic Drugs



Thrombocytopenic purpura - eltrombopag (TA293)

 9.1.4 Drugs used in autoimmune thrombocytopenic purpura



Macular degeneration (wet age-related) - aflibercept (1st line) (TA294)

11.8.2 Ocular diagnostic and peri-operative preparations



Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (TA295)

Not recommended by NICE



Crizotinib for previously treated non small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene (TA296)

Not recommended by NICE



 Ocriplasmin for treating vitreo macular traction (TA297)

 11.8.2 Ocular diagnostic and peri-operative preparations




 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)


11.8.2 Ocular diagnostic and peri-operative preparations



Bosutinib for previously treated chronic myeloid leukaemia  (TA299)

 Not recommended by NICE



 Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)

 5.3.3 Viral Hepatitis